Current News

Contact | Print version | PDF version | Send article | RSS feed

Genaissance and ParAllele BioScience Sign License and Co-Marketing Agreement

11 Apr 2005 - Genaissance Pharmaceuticals, Inc. and ParAllele BioScience, Inc. announced a joint license and co-marketing agreement to provide genetic screening technology and services for drug development and marketing.
 
Under the terms of the agreement, ParAllele is licensing more than 400 proprietary SNPs from Genaissance. These will be combined with those selected from the public domain, for a total of approximately 1,500 SNPs which are incorporated into a MegAllele(TM) DME-T assay panel developed and marketed by ParAllele. This new panel will provide full coverage of the genetic variation for more than 160 genes that are involved in drug metabolism and transport pathways. Genaissance will be the first company to offer the panel for use in a GLP-compliant environment, for research-use-only applications. The panel will be used in conjunction with arrays and instrumentation supplied by Affymetrix.